Related references
Note: Only part of the references are listed.Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design
Daniel V. T. Catenacci et al.
FUTURE ONCOLOGY (2019)
Establishment of a New Scirrhous Gastric Cancer Cell Line with FGFR2 Overexpression, OCUM-14
Tomohisa Okuno et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
Maria Kalyukina et al.
CHEMMEDCHEM (2019)
Discovery of Rogaratinib (BAY 1163877): a pan-FGFR Inhibitor
Marie-Pierre Collin et al.
CHEMMEDCHEM (2018)
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogova et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients
Yuji Mishima et al.
TARGETED ONCOLOGY (2017)
Clinicopathological and prognostic significance of circulating tumor cells in patients with head and neck cancer: a meta-analysis
Taojiao Sun et al.
ONCOTARGETS AND THERAPY (2017)
MicroRNA-23a promotes pancreatic cancer metastasis by targeting epithelial splicing regulator protein 1
Guo Wu et al.
ONCOTARGET (2017)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015 A Systematic Analysis for the Global Burden of Disease Study
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2017)
A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2017)
Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?
C. Hierro et al.
ANNALS OF ONCOLOGY (2017)
Clinical significance of circulating tumor cells in blood from patients with gastric cancer
Takaaki Arigami et al.
ANNALS OF GASTROENTEROLOGICAL SURGERY (2017)
FPA144-001: A first in human study of FPA 144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody in patients with advanced solid tumors.
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
Saori Watanabe Miyano et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Genomic and epigenomic heterogeneity in molecular subtypes of gastric cancer
Byungho Lim et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer
Masakazu Yashiro et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu et al.
NATURE MEDICINE (2015)
The detection of EpCAM+ and EpCAM- circulating tumor cells
Sanne de Wit et al.
SCIENTIFIC REPORTS (2015)
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
Nicola Aceto et al.
CELL (2014)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
Yi Liu et al.
BMC CANCER (2013)
Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis
Anna L. Paterson et al.
JOURNAL OF PATHOLOGY (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens
D. Gonzalez de Castro et al.
BRITISH JOURNAL OF CANCER (2012)
Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer
Satoshi Matsusaka et al.
CANCER SCIENCE (2011)
Japanese classification of gastric carcinoma: 3rd English edition
GASTRIC CANCER (2011)
A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models
Genshi Zhao et al.
MOLECULAR CANCER THERAPEUTICS (2011)
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial
Tanja Fehm et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer
Satoshi Matsusaka et al.
CANCER SCIENCE (2010)
Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma
Masakazu Yashiro et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
C. Simmons et al.
ANNALS OF ONCOLOGY (2009)
FGFR2 Abnormalities Underlie a Spectrum of Bone, Skin, and Cancer Pathologies
Masaru Katoh
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
ESRP1 and ESRP2 Are Epithelial Cell-Type-Specific Regulators of FGFR2 Splicing
Claude C. Warzecha et al.
MOLECULAR CELL (2009)
Share Paper
